Welcome to our dedicated page for Orthofix Med SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the pivotal FDA approvals, clinical trial outcomes, and product-liability notes buried deep inside Orthofix Medical’s 10-K can feel like navigating a surgical manual. Each filing blends device engineering jargon with regulatory language that often exceeds 250 pages, while Form 4 footnotes hide telling clues about surgeon-inventor stock moves. If you have ever asked, “How do I read the Orthofix annual report 10-K simplified or track Orthofix insider trading Form 4 transactions in real time?” you are not alone.
Stock Titan’s AI-powered analysis turns those dense documents into clear guidance. Our engine parses every Orthofix quarterly earnings report 10-Q filing, flags revenue shifts between Global Spine and Global Orthopedics, and highlights R&D spend on bone growth stimulators. It also decodes 8-K material events, so you immediately know when an FDA 510(k) clearance, product recall, or executive change hits EDGAR. Want instant alerts on Orthofix Form 4 insider transactions real-time? They arrive seconds after submission, complete with context that links share movements to upcoming product launches.
All Orthofix Medical SEC filings—10-K, 10-Q, 8-K, Form 4, DEF 14A, and more—stream here the moment they post. Use AI-generated plain-English summaries to grasp litigation reserves, understand Orthofix SEC documents with AI, and compare executive pay inside the Orthofix proxy statement executive compensation section. Whether you need Orthofix earnings report filing analysis for valuation models or are monitoring Orthofix executive stock transactions Form 4 ahead of your next trade, our platform saves hours and surfaces the disclosures that move this med-tech stock.
Orthofix Medical Inc. (OFIX) insider transaction: On 08/18/2025 Patrick Fisher, President, Global Orthopedics, sold 1,996 shares of common stock at $14.21 per share to satisfy tax withholding obligations arising from the settlement of restricted stock units. The sale was a pre-existing sell-to-cover action mandated by the Compensation and Talent Development Committee and executed without the reporting person’s discretion. Following the transaction Fisher beneficially owns 30,116 shares, which include 24,936 previously reported restricted stock units and 2,070 shares purchased under the company’s Stock Purchase Plan on 04/30/2025. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared voting and dispositive power over 2,978,000 shares of Orthofix Medical Inc. common stock, equal to 7.54% of the class based on 39,494,265 shares outstanding. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and Mr. Boyd is the managing member of Armistice Capital. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Orthofix Medical Inc. (Nasdaq: OFIX) filed an 8-K on 5 Aug 2025 to furnish, rather than file, its second-quarter 2025 earnings press release (Ex. 99.1) and an investor-relations slide deck (Ex. 99.2). The core 8-K text contains no quantitative results; all GAAP and non-GAAP figures must be obtained from the attached exhibits.
The company reiterates its extensive suite of non-GAAP metrics—constant-currency sales, free cash flow, adjusted gross profit/margin, adjusted operating & non-operating expenses, EBITDA and adjusted EBITDA—and enumerates the permitted adjustments such as share-based compensation, SeaSpine merger costs, litigation, succession charges and M6 product-line restructuring. Management argues these measures enhance period-over-period comparability, yet acknowledges their analytical limitations and provides GAAP reconciliations in the exhibits.
No guidance, outlook or numerical performance data appear in the filing itself; therefore the market impact will depend on figures contained in Exhibit 99.1.
Michael Finegan, Director at Orthofix Medical, reported acquiring 26,087 deferred stock units (DSUs) on June 18, 2025. The DSUs were granted at $0 and will fully vest on the first anniversary of the grant date, contingent on Finegan's continued service.
Following this transaction, Finegan beneficially owns a total of 57,391 securities, which includes:
- 26,087 newly granted DSUs
- 29,718 previously reported DSUs
- 1,586 shares acquired through Orthofix's Stock Purchase Plan on April 30, 2025
The DSUs represent a contingent right to receive one share of common stock each, with settlement occurring within 45 days of Finegan's termination of service with Orthofix. This Form 4 filing was submitted by attorney-in-fact J. Andres Cedron on June 23, 2025.
Orthofix Medical Inc. (OFIX) – Form 4 Insider Activity
Director Michael E. Paolucci filed a Form 4 reporting the grant of 18,841 deferred stock units (DSUs) on 06/18/2025. The transaction is coded “A,” indicating an acquisition from the issuer at $0 cost as part of equity compensation. Each DSU converts into one share of common stock and vests 100 % on the first anniversary of the grant, subject to continued board service. Vested units will be settled in common shares within 45 days after the director’s service ends.
After the award, Paolucci’s total reported beneficial ownership is 86,948 OFIX shares, which now comprises:
- 54,700 previously reported DSUs
- 1,341 shares purchased through the company’s Stock Purchase Plan on 10/31/2024
- The newly granted 18,841 DSUs
The filing shows no dispositions or sales and does not involve derivative securities other than the DSUs described. No exercise price, expiration, or cash outflow is associated with the grant. The form was signed by attorney-in-fact Geoffrey Gillespie on 06/23/2025.
Because the transaction is a routine equity award to a non-employee director, it does not directly alter Orthofix’s financial position. However, it modestly increases insider ownership, which some investors view as an indicator of alignment between the board and shareholders.
Orthofix Medical (NASDAQ:OFIX) filed a Form 4 disclosing that director Vickie L. Capps was granted 18,841 deferred stock units on 18 June 2025. These units vest in full one year after the grant date, contingent upon continued board service, and will convert into common shares within 45 days of her separation from the company. Following the award, Capps’ reported beneficial ownership increased to 21,934 shares, which includes 3,093 previously disclosed units. The award carries no purchase price and no insider sales were reported.
Orthofix Medical (NASDAQ: OFIX) filed a routine Form 4 disclosing that director Wayne Burris was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost as part of board compensation. The award vests in full one year after the grant date, provided continued service, and will convert to common stock within 45 days after the director leaves the board.
Following the grant, Burris’ total beneficial ownership increased to 50,539 shares, which includes 25,315 previously reported DSUs. The filing reports no share sales, cash proceeds, or changes to Orthofix’s operations or financial outlook.
Orthofix Medical (NASDAQ:OFIX) submitted a routine Form 4 disclosing that director Alan Lee Bazaar received 18,841 deferred stock units on 06/18/2025 as part of standard board compensation.
The units vest in full on the first anniversary of the grant date, contingent upon continued service, and convert into common stock within 45 days of the director’s termination of service. The transaction price is recorded as $0, indicating a non-cash equity award. After the grant, Bazaar beneficially owns 49,824 shares, which include 24,088 previously reported deferred stock units. No shares were sold or disposed of, and the filing notes no other material changes.
FAQ
What is the current stock price of Orthofix Med (OFIX)?
What is the market cap of Orthofix Med (OFIX)?
